Pět oximů (K-27, K-33, K-48, BI-6 a methoxim) ve srovnání s pralidoximem: in vitro reaktivace acetylcholinestrerázy červených krvinek inhibovaných paraoxonem

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F06%3A00001457" target="_blank" >RIV/60162694:G44__/06:00001457 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: in vitro reactivation of red blood cell acetylcholinesterase inhibitied by paraoxon

Popis výsledku v původním jazyce

Oximes are cholinesterase reactivators of use in poisoning with (PRX) is used clinically as an adjunct to atropine in such exposure. Clinical experience with PRX (organophosphorus compounds. Pralidoxime and other oximes) is,however, disappointing and routine use has been questioned. In addition it is known that oximes are not equally effective against all existing organophosphorus compounds. There is a clear demand for #broad spectrum# cholinesterase reactivators with a higher efficacy than PRX.Over theyears new reactivators of cholinesterase of potential clinical utility have been developed. Their chemical structures were derived from those of existing esterase reactivators, especially pralidoxime, obidoxime and HI-6. The purpose of the study was toquantify in vitro the extent of oxime (pralidoxime, K-27, K-33, K-48, methoxime and BI-6) conferred protection, using paraoxon as an inhibitor. Paraoxon (POX), the active metabolite of parathion (O,Odiethyl- O-p-nitro-phenyl phosphorothio

Název v anglickém jazyce

Five oximes (K-27, K-33, K-48, BI-6 and methoxime) in comparison with pralidoxime: in vitro reactivation of red blood cell acetylcholinesterase inhibitied by paraoxon

Popis výsledku anglicky

Oximes are cholinesterase reactivators of use in poisoning with (PRX) is used clinically as an adjunct to atropine in such exposure. Clinical experience with PRX (organophosphorus compounds. Pralidoxime and other oximes) is,however, disappointing and routine use has been questioned. In addition it is known that oximes are not equally effective against all existing organophosphorus compounds. There is a clear demand for #broad spectrum# cholinesterase reactivators with a higher efficacy than PRX.Over theyears new reactivators of cholinesterase of potential clinical utility have been developed. Their chemical structures were derived from those of existing esterase reactivators, especially pralidoxime, obidoxime and HI-6. The purpose of the study was toquantify in vitro the extent of oxime (pralidoxime, K-27, K-33, K-48, methoxime and BI-6) conferred protection, using paraoxon as an inhibitor. Paraoxon (POX), the active metabolite of parathion (O,Odiethyl- O-p-nitro-phenyl phosphorothio

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FP - Ostatní lékařské obory

OECD FORD obor

—

Projekt

<a href="/cs/project/OBVLAJEP20032" target="_blank" >OBVLAJEP20032: C-AGENS - Zdravotnická problematika ochrany živé síly proti aktuálním typům vojensky použitelných chemických látek</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2006

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Journal of Applied Toxicology

ISSN

0260-437X

e-ISSN

—

Svazek periodika

26

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

8

Strana od-do

64-71

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—